Treg Depletion by Anti-CD25 Antibody

Example 6

1×10⁵4T1 cells in 200 μl RPMI 1640 media were implanted in the 2^ndthoracic fat pad tissue of Balb/c mice. When tumours reached 50-100 mm³the mice were randomised and a single intraperitoneal flat dose of either 2 μg, 20 μg or 200 μg mouse anti-mouse CD25 (7D4) antibody was administered per mouse. At day 3 and day 9, tumour tissues and whole blood was isolated for immunophenotyping.

Results:

Antibody 7D4 exhibited Treg depleting activity in both whole blood and tumour tissue based on day 3 and day 9 post-dose analysis by immunophenotyping (FIG. 15).

Free full text: Click here

US11879014B2. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody (2024-01-23). Tusk Therapeutics Ltd. [GB], Cancer Research Technology Limited [GB]. Inventors: Anne Goubier [GB], Josephine Salimu [GB], Kevin Moulder [GB], Beatriz Goyenechea Corzo [GB], Pascal Merchiers [GB], Sergio Quezada [GB], Karl Peggs [GB], Frederick Arce Vargas [GB], Isabelle Solomon [GB].

Patent 2024

Antibody Balb c mice Blood Cd25 Fat tissue Mouse Tissue Treg cells Tumour

Top 5 similar protocols

Variable analysis

independent variables

Dose of mouse anti-mouse CD25 (7D4) antibody (2 μg, 20 μg, or 200 μg)

dependent variables

Treg depletion activity in whole blood
Treg depletion activity in tumour tissue

control variables

1×10^5 4T1 cells implanted in the 2nd thoracic fat pad tissue of Balb/c mice
Tumour size at 50-100 mm^3 prior to randomization and treatment

controls

Positive control: Not explicitly mentioned
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!